---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-007074"
form_type: "8-K"
ticker: "CRVS"
cik: "0001626971"
company_name: "Corvus Pharmaceuticals, Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T09:13:40.263097+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Corvus Q3 net loss $14.8M; cash $49.6M, CPI-818 data at ASH

## Summary
- Net loss $14.8M for Q3 2022 vs $10.7M Q3 2021; R&D expense $10.4M (+$3.4M).
- Cash, equivalents & securities $49.6M at Sep 30, 2022; projected year-end $40.5-42.5M.
- CPI-818 200 mg cohort: 1 CR lasting 25 months, 1 nodal CR 16 months, 1 PR; new data at ASH Dec 2022.
- Ciforadenant Phase 1b/2 in first-line RCC initiated with KCRC; up to 60 patients.
- IND approved in China for mupadolimab Phase 1/1b combo with pembrolizumab in lung/head & neck cancers.

## SEC filing metadata
- accession: 0001171843-22-007074
- form_type: 8-K
- ticker: CRVS
- cik: 0001626971
- company_name: Corvus Pharmaceuticals, Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626971/000117184322007074/0001171843-22-007074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626971/000117184322007074/f8k_110322.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-007074
- JSON: https://secwatch.observer/filing/0001171843-22-007074.json
- Plain text: https://secwatch.observer/filing/0001171843-22-007074.txt

## Key facts
- Earnings Releases
  Corvus Pharmaceuticals, Inc. reported financial results for three and nine months ended September 30, 2022.
  - Period: three and nine months ended September 30, 2022
  - Result: reported results
  source text: Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results
  evidence_url: https://www.sec.gov/Archives/edgar/data/1626971/000117184322007074/0001171843-22-007074-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.